Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor
24 janv. 2023 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer
17 janv. 2023 04h00 HE
|
AKAMPION
- Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options ROTTERDAM, January 17, 2023 - Pan Cancer T B.V., a...
Solid Tumors Market is Expected to Gain USD 901.27 Billion by 2029, Size, Share, Recent Trends, Developments, and Future Growth Outlook
12 janv. 2023 13h30 HE
|
Data Bridge Market Research
TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research completed a qualitative study titled "Solid Tumors Market" with 100+ market data tables, pie charts, graphs, and figures spread...
1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors
13 déc. 2022 04h00 HE
|
AKAMPION
- Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023 YONGIN, South Korea, December 13, 2022 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development...
The Global Community of Hematopoietic Cell Transplantation and Cellular Therapy Specialists Will Gather for the 2023 Tandem Meetings
30 nov. 2022 12h00 HE
|
American Society for Transplantation and Cellular Therapy (ASTCT)
CHICAGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® will connect the international community of hematopoietic...
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
18 oct. 2022 08h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and...
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
17 oct. 2022 14h27 HE
|
NKGen Biotech
SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022
12 sept. 2022 03h00 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
BioNTech und Genmab erweitern globale strategische Kollaboration zur Entwicklung und Vermarktung neuartiger Immuntherapiekandidaten
05 août 2022 06h45 HE
|
BioNTech SE
Ausweitung der Kollaboration zur Entwicklung monospezifischer Antikörperkandidaten gegen bösartige solide TumoreKollaboration nutzt Genmabs firmeneigene HexaBody®-Technologieplattform, um neuartige...
BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
05 août 2022 06h45 HE
|
BioNTech SE
Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab’s proprietary HexaBody® technology platform...